These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31064769)

  • 21. Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
    Collins TB; Laranjeira ABA; Kong T; Fulbright MC; Fisher DAC; Sturgeon CM; Batista LFZ; Oh ST
    Exp Hematol; 2024 Apr; 132():104178. PubMed ID: 38340948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
    Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
    Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
    Gjini E; Mansour MR; Sander JD; Moritz N; Nguyen AT; Kesarsing M; Gans E; He S; Chen S; Ko M; Kuang YY; Yang S; Zhou Y; Rodig S; Zon LI; Joung JK; Rao A; Look AT
    Mol Cell Biol; 2015 Mar; 35(5):789-804. PubMed ID: 25512612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of ASXL1 in hematopoiesis and myeloid diseases.
    Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
    Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation.
    Saika M; Inoue D; Nagase R; Sato N; Tsuchiya A; Yabushita T; Kitamura T; Goyama S
    Sci Rep; 2018 Oct; 8(1):15873. PubMed ID: 30367089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification.
    Uni M; Masamoto Y; Sato T; Kamikubo Y; Arai S; Hara E; Kurokawa M
    Leukemia; 2019 Jan; 33(1):191-204. PubMed ID: 29967380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
    Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
    J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A parental requirement for dual-specificity phosphatase 6 in zebrafish.
    Maurer JM; Sagerström CG
    BMC Dev Biol; 2018 Mar; 18(1):6. PubMed ID: 29544468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic therapy restores normal hematopoiesis in a zebrafish model of NUP98-HOXA9-induced myeloid disease.
    Deveau AP; Forrester AM; Coombs AJ; Wagner GS; Grabher C; Chute IC; Léger D; Mingay M; Alexe G; Rajan V; Liwski R; Hirst M; Steigmaier K; Lewis SM; Look AT; Berman JN
    Leukemia; 2015 Oct; 29(10):2086-97. PubMed ID: 26017032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Research on molecular markers for epigenetic changes in myeloid malignancies].
    Li L; Sun XM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA polymerase III component Rpc9 regulates hematopoietic stem and progenitor cell maintenance in zebrafish.
    Wei Y; Xu J; Zhang W; Wen Z; Liu F
    Development; 2016 Jun; 143(12):2103-10. PubMed ID: 27151951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
    Fisher CL; Pineault N; Brookes C; Helgason CD; Ohta H; Bodner C; Hess JL; Humphries RK; Brock HW
    Blood; 2010 Jan; 115(1):38-46. PubMed ID: 19861679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stress hematopoiesis induces a proliferative advantage in TET2 deficiency.
    Rajan V; Collett K; Woodside R; Prykhozhij SV; Moksa M; Carles A; Wong M; Liebman M; Hirst M; Berman JN
    Leukemia; 2022 Mar; 36(3):809-820. PubMed ID: 34588613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
    Sato S; Itonaga H; Taguchi M; Sawayama Y; Imanishi D; Tsushima H; Hata T; Moriuchi Y; Mishima H; Kinoshita A; Yoshiura KI; Miyazaki Y
    Int J Hematol; 2018 Aug; 108(2):213-217. PubMed ID: 29417354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.
    Jing CB; Prutsch N; He S; Zimmerman MW; Landesman Y; Look AT
    Br J Haematol; 2023 May; 201(3):489-501. PubMed ID: 36746437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
    Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
    Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
    [No Abstract]   [Full Text] [Related]  

  • 39. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
    Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
    Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.